Browsing Tag

GB-102

Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

Jason Junior Nov 11, 2022

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular…

Health

Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the…

Jason Junior May 19, 2022

BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa…

Health

Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b…

Jason Junior Sep 28, 2021

55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden for patients participating in Extension StudyGB-102 1mg…